Core Insights - Moderna reported revenue of $142 million for the quarter ended June 2025, a decrease of 41.1% year-over-year, with an EPS of -$2.13 compared to -$3.33 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $127.17 million by 11.66%, while the EPS also surpassed the consensus estimate of -$2.99 by 28.76% [1] Revenue Breakdown - Product sales in the United States were $88 million, significantly higher than the average estimate of $28.31 million, but represented a year-over-year decline of 45.7% [4] - Product sales in the Rest of the World reached $26 million, below the average estimate of $42.95 million, but showed an 18.2% increase year-over-year [4] - Net product sales totaled $114 million, exceeding the average estimate of $81.42 million, but reflected a 38% decrease compared to the previous year [4] - Other revenue amounted to $28 million, slightly above the average estimate of $25.13 million, but indicated a 50.9% decline year-over-year [4] - Grant revenue was reported at $5 million, compared to the average estimate of $6.16 million [4] - Licensing and royalty revenue was $2 million, significantly lower than the average estimate of $10.65 million [4] - Collaboration revenue reached $4 million, below the average estimate of $7.5 million [4] Stock Performance - Over the past month, Moderna's shares have returned -3.1%, contrasting with the Zacks S&P 500 composite's increase of 2.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]